Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (MP‐424), pegylated interferon and ribavirin for 12 weeks

Aim:  To evaluate the efficacy and safety of the triple treatment with telaprevir (MP‐424), pegylated interferon (PEG‐IFN) and ribavirin during 12 weeks on‐treatment.

[1]  S. Zeuzem.  Telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in chronic hepatitis C patients. , 2008, Journal of hepatology.

[2]  J. McHutchison,et al.  Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. , 2008, Journal of hepatology.

[3]  B. Spiegel,et al.  Predictors of treatment in patients with chronic hepatitis C infection—Role of patient versus nonpatient factors , 2007, Hepatology.

[4]  Tara L. Kieffer,et al.  Antiviral activity of telaprevir (VX‐950) and peginterferon alfa‐2a in patients with hepatitis C , 2007, Hepatology.

[5]  Tara L. Kieffer,et al.  Telaprevir and pegylated interferon–alpha‐2a inhibit wild‐type and resistant genotype 1 hepatitis C virus replication in patients , 2007, Hepatology.

[6]  J. Hoofnagle,et al.  New therapies for hepatitis C , 2007, Hepatology.

[7]  A. Kwong,et al.  Phenotypic and Structural Analyses of Hepatitis C Virus NS3 Protease Arg155 Variants , 2007, Journal of Biological Chemistry.

[8]  Lisa I. Backus,et al.  Predictors of response of U.S. veterans to treatment for the hepatitis C virus , 2007 .

[9]  L. Lang.  HCV findings presented at EASL: long-term follow-up and the criteria of a cure. , 2007, Gastroenterology.

[10]  Yoshiyuki Suzuki,et al.  Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. , 2007, Journal of hepatology.

[11]  P. Marcellin,et al.  Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α‐2a (40 kd)/ribavirin therapy , 2006, Hepatology.

[12]  A. Kwong,et al.  Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. , 2006, Infectious disorders drug targets.

[13]  Yoshiyuki Suzuki,et al.  Predictive factors of virological non‐response to interferon–ribavirin combination therapy for patients infected with hepatitis C virus of genotype1b and high viral load , 2006, Journal of medical virology.

[14]  A. Kwong,et al.  In Vitro Studies of Cross-resistance Mutations against Two Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061* , 2005, Journal of Biological Chemistry.

[15]  H. Goto,et al.  Treatment of Chronic Hepatitis C with Interferon Alone or Combined with Ribavirin in Japan , 2005, Intervirology.

[16]  J. Tanaka,et al.  National Prevention of Hepatocellular Carcinoma in Japan Based on Epidemiology of Hepatitis C Virus Infection in the General Population , 2005, Intervirology.

[17]  K. Tanikawa,et al.  Impact of daily high-dose IFNalpha-2b plus ribavirin combination therapy on reduction of ALT levels in patients with chronic hepatitis C with genotype 1 and high HCV RNA levels. , 2005, Hepatology research : the official journal of the Japan Society of Hepatology.

[18]  Yoshiyuki Suzuki,et al.  Early viral kinetics and treatment outcome in combination of high‐dose interferon induction vs. pegylated interferon plus ribavirin for naïve patients infected with hepatitis C virus of genotype 1b and high viral load , 2005, Journal of medical virology.

[19]  C. Datz,et al.  Retreatment of patients with chronic hepatitis C not responding to interferon/ribavirin combination therapy with daily interferon plus ribavirin plus amantadine , 2004, Wiener Klinische Wochenschrift.

[20]  Yoshiyuki Suzuki,et al.  High-dose interferon alpha-2b induction therapy in combination with ribavirin for Japanese patients infected with hepatitis C virus genotype 1b with a high baseline viral load , 2004, Journal of Gastroenterology.

[21]  G. Davis.  Monitoring of viral levels during therapy of hepatitis C , 2002, Hepatology.

[22]  L. Seeff,et al.  Natural history of chronic hepatitis C , 2002, Hepatology.

[23]  M. Shiffman.  Retreatment of patients with chronic hepatitis C , 2002, Hepatology.

[24]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[25]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[26]  L. Seeff,et al.  Natural history of hepatitis C , 1997, Hepatology.

[27]  Edoardo Cervoni,et al.  Hepatitis C , 1998, The Lancet.

[28]  N Enomoto,et al.  Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. , 1996, The New England journal of medicine.

[29]  Derek B Boothroyd,et al.  Predictors of response of US veterans to treatment for the hepatitis C virus. , 2007, Hepatology.

[30]  R. W. Mccollum.  The natural history of hepatitis. , 1969, Bulletin of the New York Academy of Medicine.